Targeted therapy nel paziente anziano con carcinoma prostatico ormono-resistente

Translated title of the contribution: Targeted therapy in patients with metastatic hormone-refractory prostate cancer

Silvana Leo, C. Accettura, V. Lorusso

Research output: Contribution to journalArticle

Abstract

Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.

Original languageItalian
Pages (from-to)58-66
Number of pages9
JournalGeriatric and Medical Intelligence
Volume19
Issue number1
Publication statusPublished - 2010

Fingerprint

Prostatic Neoplasms
Hormones
docetaxel
Biological Therapy
Therapeutics
Prednisone
Drug-Related Side Effects and Adverse Reactions
Survival
Population
Neoplasms

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Targeted therapy nel paziente anziano con carcinoma prostatico ormono-resistente. / Leo, Silvana; Accettura, C.; Lorusso, V.

In: Geriatric and Medical Intelligence, Vol. 19, No. 1, 2010, p. 58-66.

Research output: Contribution to journalArticle

@article{35254e1c31c14f0f9105518ef7c6139d,
title = "Targeted therapy nel paziente anziano con carcinoma prostatico ormono-resistente",
abstract = "Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.",
keywords = "Hormone-refractory prostate cancer, Oncogeriatry, Targeted therapies",
author = "Silvana Leo and C. Accettura and V. Lorusso",
year = "2010",
language = "Italian",
volume = "19",
pages = "58--66",
journal = "Geriatric and Medical Intelligence",
issn = "1121-8460",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - Targeted therapy nel paziente anziano con carcinoma prostatico ormono-resistente

AU - Leo, Silvana

AU - Accettura, C.

AU - Lorusso, V.

PY - 2010

Y1 - 2010

N2 - Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.

AB - Hormone-refractory prostate cancer is common and only the combination of docetaxel and prednisone has been shown to improve survival. Targeted therapies have revolutionized the treatment of cancer. Advances in our understanding of the molecular mechanism underlying prostate cancer progression has translated into a variety of treatment approaches. However, the treatment of elderly patients with these new biological therapies remains a challenge and few data are available concerning the toxicity of biological drugs in the elderly population.

KW - Hormone-refractory prostate cancer

KW - Oncogeriatry

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=77951055309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951055309&partnerID=8YFLogxK

M3 - Articolo

VL - 19

SP - 58

EP - 66

JO - Geriatric and Medical Intelligence

JF - Geriatric and Medical Intelligence

SN - 1121-8460

IS - 1

ER -